Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 10/20 | 0.64 |
| ▸ | UMPS | P11172 | 1/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.58 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.58 |
| ▸ | NT5E | P21589 | 2/20 | 0.51 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19998422 | 1.00 | P2RY6 (0.64) | P2RY6UMPSP2RY2P2RY4NT5E | |
| SCHEMBL15279691 | 0.92 | P2RY6 (0.76) | P2RY6P2RY2P2RY4NT5E | |
| SCHEMBL21450027 | 0.92 | P2RY6 (0.76) | P2RY6P2RY2P2RY4NT5E | |
| SCHEMBL15276355 | 0.92 | P2RY6 (0.76) | P2RY6P2RY2P2RY4NT5E | |
| SCHEMBL19308867 | 0.92 | P2RY6 (0.76) | P2RY6P2RY2P2RY4NT5E | |
| SCHEMBL20013630 | 0.92 | P2RY6 (0.58) | P2RY6UMPSP2RY2P2RY4NT5E | |
| SCHEMBL20013771 | 0.92 | P2RY6 (0.58) | P2RY6UMPSP2RY2P2RY4NT5E | |
| SCHEMBL20013434 | 0.92 | P2RY6 (0.58) | P2RY6UMPSP2RY2P2RY4NT5E | |
| SCHEMBL19998464 | 0.91 | P2RY6 (0.73) | P2RY6P2RY2P2RY4NT5E | |
| SCHEMBL20003863 | 0.91 | P2RY6 (0.73) | P2RY6P2RY2P2RY4NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180085386-A1 | URIDINE MONOPHOSPHATE AND TRIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085386-A1 | URIDINE MONOPHOSPHATE AND TRIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | P2RY6 1/4885UMPS 3/4885P2RY2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.